What is CF PharmTech?
CF PharmTech, also known as 长风药业股份有限公司, is a specialized pharmaceutical company committed to developing and delivering high-quality inhalation drugs globally. The company's integrated management solutions target critical respiratory conditions such as allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). Their product portfolio encompasses a range of inhalation formulations, including aerosol sprays, dry powder inhalers, and nasal sprays, addressing a significant and growing demand for effective respiratory health treatments. The company's focus on research and development positions it as a key player in advancing inhalation therapy.
How much funding has CF PharmTech raised?
CF PharmTech has raised a total of $205M across 3 funding rounds:
Series D
$65M
Series E
$90M
Series F
$50M
Series D (2017): $65M, investors not publicly disclosed
Series E (2020): $90M led by Xiangcheng Financial Holdings, CMB International, New Alliance Capital, Everest Venture Capital, GTJA Investment, GT Capital, Co-stone Asset Management, Longmen Venture Capital, CR-CP Life Science Fund, Finnova Capital, and Oriza Holdings
Series F (2020): $50M, investors not publicly disclosed
Key Investors in CF PharmTech
New Alliance Capital
New Alliance Capital is a venture capital firm based in Shanghai, China, known for its investments in various industries. Their participation suggests a strategic interest in CF PharmTech's growth and market potential.
Oriza Holdings
Oriza Holdings is a significant investment firm with a focus on life sciences and healthcare. Their involvement indicates a strong belief in CF PharmTech's innovative pharmaceutical solutions and market strategy.
Everest Venture Capital
Everest Venture Capital is an investment entity that likely focuses on high-growth companies. Their backing of CF PharmTech points to the company's strong potential within the pharmaceutical and biotech sectors.
What's next for CF PharmTech?
The substantial enterprise-level funding, including the recent major strategic investment, positions CF PharmTech for accelerated expansion and further innovation in the respiratory drug market. This capital infusion is likely to fuel advancements in their R&D pipeline, potentially leading to new product launches and the enhancement of existing inhalation technologies. The company's strategic focus on integrated solutions for respiratory diseases suggests a trajectory towards solidifying its market leadership and expanding its global reach, further cementing its role as a vital contributor to public health.
See full CF PharmTech company page
